Immunotherapy Granted Orphan Drug Status for Ovarian Cancer

Article

The FDA has granted Orphan Drug Designation to the immunotherapy DPX-Survivac, which is in development for the treatment of ovarian cancer.

DPX-Survivac is also being tested in large B-cell lymphoma

The US Food and Drug Administration (FDA) granted Orphan Drug Designation to an immunotherapy known as DPX-Survivac, which is in development for the treatment of ovarian cancer. The drug has produced some positive phase I results and is also being tested in recurrent diffuse large B-cell lymphoma.

“Receiving Orphan Drug Designation for ovarian cancer underlines the fact that DPX-Survivac may address a significant unmet medical need for this important disease,” said Marc Mansour, the CEO of the drug’s developer, Immunovaccine, in a press release. “Immunotherapy could change the way we treat all cancers in the future, and we plan to continue to study of DPX-Survivac for the treatment of ovarian cancer as well as other solid tumor types and blood cancers.”

The immunotherapy targets the tumor antigen survivin, which the company says is found in more than 90% of ovarian tumors. The orphan drug designation follows an earlier fast track designation for DPX-Survivac, specifically for patients with advanced ovarian, fallopian tube, or peritoneal cancer with no measurable disease following initial surgery and front-line therapy.

The FDA’s new move follows the publication of results from a small phase I trial in OncoImmunology in May of this year. DPX-Survivac was tested in combination with the immune-modulator metronomic cyclophosphamide in 19 patients with ovarian cancer. They found that the therapy induced survivin-specific immune responses in all patients, and that higher dose of the vaccine and cyclophosphamide generated responses of higher magnitude.

“The level of immune activation observed both quantitatively and qualitatively is unprecedented in a cancer population,” wrote study authors led by Neil L. Berinstein, MD, of Sunnybrook Health Sciences Centre in Toronto. “This vaccine combination may be an ideal candidate for further combination with other promising immunotherapeutics such as checkpoint inhibitors.”

Though the trial was not powered for observation of clinical activity, the authors noted that after 6 months, 12 of 18 patients remained without clinical progression. Further follow-up is ongoing.

According to ClinicalTrials.gov, DPX-Survivac is being tested in ovarian, fallopian, and peritoneal cancer, as well as in a phase II study of patients with recurrent diffuse large B-cell lymphoma. That trial also uses the immunotherapy in combination with cyclophosphamide.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content
Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

Rintatolimod Combo Yields Clinical Benefit in Recurrent Ovarian Cancer

April 11th 2024
Article

Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer

March 28th 2024
Article

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.

Rezatapopt Yields Early Responses, Safety in Advanced Ovarian Cancer

March 24th 2024
Article

Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.

Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.

FDA Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

March 22nd 2024
Article

Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.